This dual sequential therapy can be repeated many times until the cancer is eliminated.'

The concept has been tested successfully in mice and dogs. Human trials are set to commence by the end of August.

Brahmbhatt said several hundred cancer patients have 'written to us seeking to participate in our clinical trials. However, this process of screening patients and enrolment in the trial will be carried out by the oncologists (cancer specialists) at the hospitals where the trial will be done.'

The trial, with over 40 cancer patients, can take over eight months.

Brahmbhatt said if early trial results are positive, the firm may try to treat a cancer patient who does not have any other option.

EnGeneIC is working towards establishing collaborations or licensing deals with major pharmaceutical companies in the US, Europe and Japan with a view to co-developing several anti-cancer therapeutics based on the EDV technology.

'This will allow us to fast track the process to get such therapeutics out on the market so that cancer patients worldwide may benefit,' Brahmbhatt was quoted by Indian Link as saying. It can take three to four years to get such a therapeutic to market.

Relapse of a cancer is common and often the tumour becomes resistant to drugs when the relapse does take place. These are the patients whose hopes can revive due to Brahmbhatt's breakthrough.